Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA Plus Retifanlimab in Recurrent IDH-Mutant Glioma
NCT05345002Phase 2Recruiting
- Start
- Nov 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab, tretinoin in glioma, astrocytoma, Oligodendroglioma (OG). Started Nov 2022; status: recruiting.
02
Drugs
retifanlimabtretinoin
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05345002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345002.